Published in Hepatitis Weekly, August 28th, 2006
The new PhysicianForum report entitled Hepatitis B: New Antivirals Replacing the Old', also finds that while clinician use of Baraclude will increase, Baraclude and Gilead's Hepsera are facing hurdles in achieving favorable tier status amongst surveyed private health...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.